Ankylosing Spondylitis Market Projected to Reach $10.6 Billion by 2033, Driven by Rising Autoimmune Diseases and Aging Population

April 2025 - The Global Ankylosing Spondylitis Market Report, published by Emergen Research, offers an industry-wide assessment of the Ankylosing Spondylitis market, which is inclusive of the most crucial factors contributing to the growth of the industry. The latest research report comprises an extensive analysis of the micro- and macro-economic indicators that influence the global market development during the forecast period of 2024-2033

The global Ankylosing Spondylitis market is poised for significant growth, with revenue expected to increase from $5.8 billion in 2024 to $10.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.90%. This growth is fueled by several key factors, including the rising prevalence of autoimmune diseases, advancements in therapeutic options, increasing awareness, and the growing geriatric population.

You Can Download Free Sample PDF Copy Of This Report At: https://www.emergenresearch.com/request-sample/3985

Key Growth Drivers

1. Rising Geriatric Population:

The aging global population is a major contributor to market expansion. According to the United Nations Department of Economic and Social Affairs (UN DESA), the number of people aged 65 and older is projected to double from 761 million in 2021 to 1.6 billion by 2050. Elderly individuals are particularly susceptible to ankylosing spondylitis, a chronic inflammatory condition affecting mobility and causing pain. Treatments for ankylosing spondylitis are increasingly sought after to improve quality of life for this demographic.

2. Increasing Prevalence of Autoimmune Diseases:

Autoimmune diseases, including ankylosing spondylitis, are becoming more common worldwide due to genetic predisposition and environmental factors. These conditions occur when the immune system mistakenly attacks healthy tissues, leading to inflammation and damage. For instance, Canada reported over 320,000 cases of inflammatory bowel disease (IBD) in 2023, with prevalence expected to grow annually by 2.44%. This trend highlights the broader rise in autoimmune disorders globally, driving demand for effective treatments.

3. Advancements in Therapeutic Options:

Innovative therapies are reshaping the landscape of ankylosing spondylitis treatment. In April 2022, AbbVie Inc.'s RINVOQ was approved by the U.S. Food and Drug Administration (FDA) as an oral treatment option for adults with active ankylosing spondylitis who did not respond to TNF blockers. RINVOQ demonstrated rapid efficacy and safety in clinical trials, offering significant relief from symptoms such as back pain and improving physical functioning. Such advancements not only enhance patient care but also stimulate market growth.

Challenges Facing Market Growth

Despite promising developments, the high cost of biological medications and long-term treatment poses a significant challenge to market expansion. While these therapies are effective in managing symptoms and slowing disease progression, their expense often limits accessibility for patients. Many individuals may discontinue treatment or fail to adhere due to financial constraints, impacting overall outcomes. Additionally, extended treatment durations increase costs for healthcare systems, potentially hindering widespread adoption.

Distribution Channel Insights

The Ankylosing Spondylitis market is segmented by distribution channels into hospital pharmacies, retail pharmacies, online pharmacies, and others:

Hospital Pharmacies:
Hospital pharmacies dominated the market in 2024 due to their ability to stock specialized medications and provide infusion therapies that require healthcare provider supervision. The rising incidence of ankylosing spondylitis also contributes to increased hospital visits.

Retail Pharmacies:
Retail pharmacies are expected to be the fastest-growing segment during the forecast period due to their accessibility and convenience. Extended operating hours and widespread locations make it easier for patients to obtain medications without frequent hospital visits. The availability of biosimilars further supports growth in this segment.

Request Customization: https://www.emergenresearch.com/request-for-customization/3985

Competitive Terrain:

The global Ankylosing Spondylitis industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

Some major companies included in the Ankylosing Spondylitis market report are:

AbbiVie, Inc.

Amgen, Inc.

Pfizer, Inc.

Johnson & Johnson, Inc.

Novartis AG

UCB, Inc.

Eli Lilly and Company

Merck & Co., Inc.

Zydus Lifescience ltd.

Izana Bioscience

The report further divides the Ankylosing Spondylitis market into key segments such as types, applications, end-user industries, technologies, and key regions of the market. The report also sheds light on the segment and region exhibiting promising growth in the Ankylosing Spondylitis market.

Ankylosing Spondylitis Market Segmentation Analysis

Drug Class Outlook (Revenue, USD Billion; 2020-2033)

Non-Steroidal Anti Inflammatory Drug(NSAID)

TNF Inhibitors

Humira

Simponi

Remicade

Enbrel

Cimzia

Other TNF Inhibitors

Other Drug Classes

Distribution Channel Outlook (Revenue, USD Billion; 2020-2033)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacies

Others

Browse Full Report: https://www.emergenresearch.com/industry-report/ankylosing-spondylitis-market

Regional Outlook:

North America (the U.S., Canada, Mexico)

Europe (the U.K., Germany, France, Italy)

Asia Pacific (India, China, Japan, Korea)

Latin America (Brazil, Argentina, Ecuador, Chile)

Middle East & Africa (Egypt, Turkey, Saudi Arabia, Iran)

Key Questions Answered by the Report:

Which region is expected to dominate the market in the coming years?

What are the recent technological and product advancements occurring in the market?

What are the key strategies adopted by the prominent players in the Ankylosing Spondylitis market?

What are the key product types and applications of the Ankylosing Spondylitis industry?

What is the outcome of SWOT analysis and Porter's Five Forces analysis?

How is the competitive landscape of the Ankylosing Spondylitis market?

Who are the key players in the industry?

What is the growth rate of the industry over the coming years?

What will be the valuation of the Ankylosing Spondylitis Market by 2033?

Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.

14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.